We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 207

Post-Actavis rulings focus on what constitutes a payment in reverse-payment settlements

  • Skadden Arps Slate Meagher & Flom LLP
  • -
  • USA
  • -
  • January 21 2015

Nearly a year and a half after the Supreme Court's landmark decision in Federal Trade Commission v. Actavis, Inc., 133 S.Ct. 2223 (2013), the hotly

IPtronix sues Avago for antitrust violations for filing allegedly baseless Section 337 complaint

  • King & Spalding LLP
  • -
  • USA
  • -
  • January 16 2015

On December 29, 2014, IPtronics Inc. and Mellanox Technologies Denmark, APS filed a complaint in the U.S. District Court for the Northern District of

In re: Nexium plaintiffs seek new trial

  • Patterson Belknap Webb & Tyler LLP
  • -
  • USA
  • -
  • January 7 2015

As reported previously, the first post-Actavis jury verdict in a "reverse payment" antitrust case handed a win to the defendants. Now, plaintiffs in

Made in Canada approach to pay for delay: bureau at odds with US approach

  • Cassels Brock & Blackwell LLP
  • -
  • USA
  • -
  • December 8 2014

Last week, a US Federal Court ruled that AstraZeneca Plc's payment to Ranbaxy Laboratories Ltd. to delay a generic version of heartburn medication

FDA citizen petition may give rise to antitrust liability; factual issues exist concerning whether ANDA infringement claim was objectively baseless

  • Fish & Richardson PC
  • -
  • USA
  • -
  • December 6 2014

Federal Circuit reverses summary judgment of no sham litigation related to an infringement suit and FDA citizen’s petition but affirms summary

N.D. Cal. grants patent holder judgment on the pleadings on Defendants’ antitrust and unfair competition counterclaims with leave to amend

  • Kelley Drye & Warren LLP
  • -
  • USA
  • -
  • November 25 2014

The Northern District of California recently granted judgment on the pleadings in favor of patent-plaintiff ChriMar Systems, Inc. on antitrust and

Second Circuit rules that foreign anticompetitive use of royalty-free patent is insufficient to establish a domestic effect giving rise to claim under the FTAIA

  • Baker Botts LLP
  • -
  • USA
  • -
  • November 7 2014

Standards essential patents can run afoul of United States antitrust law when the patent owner acts in a matter which creates anticompetitive risks

Legal FAQ: Section 337 investigations before the International Trade Commission

  • Fenwick & West LLP
  • -
  • USA
  • -
  • October 22 2014

The U.S. International Trade Commission (“ITC”) investigates claims of unfair competition under Section 337 of the Tariff Act of 1930, as amended

Conduct outside the U.S. violates U.S. antitrust law only if it reasonably and proximately caused a domestic effect that caused the plaintiff's injury

  • Finnegan, Henderson, Farabow, Garrett & Dunner LLP
  • -
  • USA
  • -
  • October 21 2014

In a recent Second Circuit case, a USB connector manufacturer alleged that a number of its competitors engaged in anticompetitive behavior in

Allegations that defendants provided product for “free” state claims under California’s UPA and UCL, notwithstanding that “cost” of product was recouped by overcharging for shipping

  • Sheppard Mullin Richter & Hampton LLP
  • -
  • USA
  • -
  • October 10 2014

Plaintiff Bebe Au Lait sells nursing covers. It was the first company to make and sell, pursuant to patent, a flexible, convex stiffener located